source
- Replimune secures FDA approval for RP1 therapy in advanced melanoma as Eli Lilly reports strong Q2 earningsReplimune announced that the FDA has granted market approval for its oncolytic immunotherapy RP1, aimed at treating advanced melanoma. The decision follows two earlier rejections and a contentious…
- Neurocrine's Prader-Willi drug Vykat XR linked to multiple deaths and serious side effectsA group of physicians and experts in Prader-Willi syndrome warned clinicians about safety concerns with Vykat XR, a drug approved by the FDA in March 2025 to reduce the intense hunger in patients w…